M&A Deal Summary

Aceragen Acquires Arrevus

On October 28, 2021, Aceragen acquired life science company Arrevus

Acquisition Highlights
  • This is Aceragen’s 1st transaction in the Life Science sector.
  • This is Aceragen’s 1st transaction in the United States.
  • This is Aceragen’s 1st transaction in North Carolina.

M&A Deal Summary
Date 2021-10-28
Target Arrevus
Sector Life Science
Buyer(s) Aceragen
Deal Type Add-on Acquisition

Target

Arrevus

Durham, North Carolina, United States
Arrevus is a biotechnology company whose mission is to eliminate the threat of antibiotic resistance and improve treatment outcomes for serious infectious diseases. The company is applying evolutionary templates to develop first-in-class proprietary anti-infectives known as Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs). Arrevus was formed in 2015 and is based in Durham, North Carolina.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Aceragen

Research Triangle Park, North Carolina, United States
Category Company
Sector Life Science
DESCRIPTION

Aceragen is a biopharmaceutical company developing innovative therapeutics for rare and orphan diseases. The Company is advancing ACG-801 (rhAC) as an investigational enzyme replacement therapy for the treatment of patients with Farber disease and potentially other diseases associated with the dysregulation of ceramide metabolism, including cystic fibrosis. Its other development lead is ACG-721, an oral small molecule candidate for cystic fibrosis pulmonary exacerbations and related orphan infectious diseases. Aceragen is based in Research Triangle Park, North Carolina.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (North Carolina) 1 of 1
Country (United States) 1 of 1
Year (2021) 1 of 1
Mergr

Product

Company

Legal